RETRACTED: Cost-utility analysis of trastuzumab combined with Docetaxel for patients with HER-2 positive metastatic breast cancer - real world claim data.
- DOI
- 10.1177/1078155218755548
- Published
- 2018 Sep
- Container
- Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
- Publisher
- Not recorded
- Open access
- no
Credibility signals
serious concern Score 8/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- serious concernRetraction Watch retraction: 1 retraction notice matched this DOI.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1177/1078155218755548,
title = {RETRACTED: Cost-utility analysis of trastuzumab combined with Docetaxel for patients with HER-2 positive metastatic breast cancer - real world claim data.},
author = {Leung HW and Chan AL and Wang SY},
year = {2018},
journal = {Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners},
doi = {10.1177/1078155218755548},
url = {https://doi.org/10.1177/1078155218755548}
}RIS
TY - JOUR TI - RETRACTED: Cost-utility analysis of trastuzumab combined with Docetaxel for patients with HER-2 positive metastatic breast cancer - real world claim data. AU - Leung HW AU - Chan AL AU - Wang SY PY - 2018 JO - Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners DO - 10.1177/1078155218755548 UR - https://doi.org/10.1177/1078155218755548 ER -
APA
HW, L., AL, C., & SY, W. (2018). RETRACTED: Cost-utility analysis of trastuzumab combined with Docetaxel for patients with HER-2 positive metastatic breast cancer - real world claim data.. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. https://doi.org/10.1177/1078155218755548
Source records
- pubmed · retrieved 2026-09-25T10:47:18.132Z
- europe-pmc · retrieved 2026-09-25T10:47:18.114Z